PACIFIC EDGE LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.082 NZD | -2.38% |
|
-3.53% | -29.91% |
| 09/04 | Pacific Edge Reports Steady Growth in Bladder Cancer Test Volumes in Fiscal Q4 | MT |
| 14/03 | New Zealand Shares Flat on Thursday; Pacific Edge's Chair to Retire | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 66.56M 112M 5.55B |
|---|---|---|---|---|---|
| Net income 2024 * | -28M -47.15M -2.33B | Net income 2025 * | -22M -37.05M -1.83B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 47.65M 80.24M 3.97B | Net cash position 2025 * | 23.52M 39.61M 1.96B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.33
x | P/E ratio 2025 * |
-3.03
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pacific Edge Limited
More news
| 1 day | -2.38% | ||
| 1 week | -3.53% | ||
| Current month | -3.53% | ||
| 1 month | -4.65% | ||
| 3 months | -21.90% | ||
| 6 months | -19.61% | ||
| Current year | -29.91% |
1 week
0.08
0.09
1 month
0.080.09
Current year
0.080.13
1 year
0.050.50
3 years
0.051.59
5 years
0.051.59
10 years
0.041.59
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Meintjes
CEO | Chief Executive Officer | - | 17/22/17 |
Grant Gibson
DFI | Director of Finance/CFO | - | 16/19/16 |
Justin Harvey
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chris Gallaher
CHM | Chairman | - | 01/16/01 |
Bryan Williams
BRD | Director/Board Member | 74 | 04/13/04 |
Anthony Barclay
BRD | Director/Board Member | - | 21/22/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.93% | 81 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.082 | -2.38% | 314,180 |
| 24/24/24 | 0.084 | +1.20% | 109,773 |
| 23/24/23 | 0.083 | +1.22% | 576,846 |
| 22/24/22 | 0.082 | -3.53% | 487,199 |
| 19/24/19 | 0.085 | 0.00% | 113,684 |
End-of-day quote New Zealand S.E., April 26, 2024
More quotes
Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas, and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.
Calendar
30/05/2024
- Q4 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.082
NZD
Average target price
0.135
NZD
Spread / Average Target
+64.63%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.91% | 39.47M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PEB Stock
